Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline of cancer drugs for 2.7 billion euros, or $2.9 billion. The Swiss drugmaker will pay 68 euros, or around $73, per share, nearly twice Morphosys’s average trading price over the last month.
At the center of the deal is pelabresib, a blood cancer pill that in November posted mixed results in a Phase 3 trial.
The drug hit the primary endpoint, significantly reducing spleen volume in patients with a rare cancer called myelofibrosis compared to placebo. But the drug failed to make a significant impact on symptoms — 52% of patients on pelabresib saw their scores on a symptom scale fall by half, but so did 46% of patients on placebo. The result raised questions about whether regulators would approve the drug and if it had a commercial market.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect